{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-001962","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.226214+00:00","generated_at":"2026-06-20T19:33:47.663864+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023","bullets":["Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.","Caroline Baumal, M.D., appointed CMO effective Jan 3, 2023, succeeding Dr. Grossi.","Dr. Grossi will continue at Apellis through Feb 28, 2023 to assist transition and pegcetacoplan launch preparations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-001962","json":"https://secwatch.observer/filing/0001193125-23-001962.json","markdown":"https://secwatch.observer/filing/0001193125-23-001962.md","text":"https://secwatch.observer/filing/0001193125-23-001962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/d436534d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:33:47.663864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4164fe6249","claim":"Federico Grossi departed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..","evidence_excerpt":"Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"leaving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"d5f3d77d5c","claim":"Caroline Baumal was appointed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..","evidence_excerpt":"Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}